Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
Next Generation Sequencing (NGS) ermöglicht ein besseres Verständnis genetischer krankheitsassoziierter Faktoren un…
Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billio…
Erstmalige Vorstellung der Daten zum Gesamtüberleben aus der finalen Analyse der Phase-III-Studie ARAMIS zur Untersuchun…
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-c…
Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics' investigati…
Clinical study demonstrates proof-of-concept for active personalized immunotherapy approach in a pioneering multi-center…
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today introduced seamless next-generation sequencing (NGS) solut…
New direction for omega-3 science with Accelon absorption technology BASF sponsors New Investigator Awards to support ri…
While developed countries represent established and thriving markets for chocolate, a shift in consumer taste preference…